Literature DB >> 29391232

Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Samaresh Sau1, Hashem O Alsaab2, Ketki Bhise3, Rami Alzhrani2, Ghazal Nabil4, Arun K Iyer5.   

Abstract

Several cancer immunotherapy approaches have been recently introduced into the clinics and they have shown remarkable therapeutic potentials. The groundbreaking cancer immunotherapeutic agents function as a stimulant or modulator of the body immune system to fight against or kill cancers. Although targeted immunotherapies such as immune check point inhibitors (CTLA-4 or PD-1/PD-L1), DNA vaccination and CAR-T therapy are revolutionizing cancer treatment, the delivery efficacy can be further improved while their off-target toxicity can be mitigated through nanotechnology approaches. Recent research has demonstrated that nanotechnology has multifaceted role for (i) reeducating tumor associated macrophages (TAM) to function as tumor suppressor agent, (ii) serving as an efficient alternative for Chimeric Antigen Receptor (CAR)-T cell generation and transduction, and (iii) selective knockdown of Kras oncogene addiction by nano-Crisper-Cas9 delivery system. The function of host immune stimulatory signals and tumor immunotherapies can further be improved by repurposing of nanomedicine platform. This review summarizes the role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CAR-T; CRISPR-Cas9; CTLA-4 targeting; Cancer; Cytokine storm; Dendritic cell vaccine; Immunotherapy; Nanomedicine; PD-1/PDL-1 targeting; Tumor associated macrophages

Mesh:

Substances:

Year:  2018        PMID: 29391232      PMCID: PMC5847475          DOI: 10.1016/j.jconrel.2018.01.028

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  93 in total

1.  Grand challenges in modulating the immune response with RNAi nanomedicines.

Authors:  Meir Goldsmith; Shoshy Mizrahy; Dan Peer
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

Review 2.  Liposomal siRNA nanocarriers for cancer therapy.

Authors:  Bulent Ozpolat; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2013-12-30       Impact factor: 15.470

3.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott Gettinger; Naiyer A Rizvi; Laura Q Chow; Hossein Borghaei; Julie Brahmer; Neal Ready; David E Gerber; Frances A Shepherd; Scott Antonia; Jonathan W Goldman; Rosalyn A Juergens; Scott A Laurie; Faith E Nathan; Yun Shen; Christopher T Harbison; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

4.  The immune checkpoint inhibitors: where are we now?

Authors:  Rachel M Webster
Journal:  Nat Rev Drug Discov       Date:  2014-10-27       Impact factor: 84.694

5.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

6.  Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue.

Authors:  Kaustubh A Gawde; Prashant Kesharwani; Samaresh Sau; Fazlul H Sarkar; Subhash Padhye; Sushil K Kashaw; Arun K Iyer
Journal:  J Colloid Interface Sci       Date:  2017-02-14       Impact factor: 8.128

7.  Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation.

Authors:  Milada Mahic; Sheraz Yaqub; Tone Bryn; Karen Henjum; Dag M Eide; Knut M Torgersen; Einar M Aandahl; Kjetil Taskén
Journal:  J Leukoc Biol       Date:  2008-02-12       Impact factor: 4.962

8.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

9.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.

Authors:  Brandon Kwong; Haipeng Liu; Darrell J Irvine
Journal:  Biomaterials       Date:  2011-04-22       Impact factor: 12.479

10.  Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.

Authors:  H F Moffett; M E Coon; S Radtke; S B Stephan; L McKnight; A Lambert; B L Stoddard; H P Kiem; M T Stephan
Journal:  Nat Commun       Date:  2017-08-30       Impact factor: 14.919

View more
  33 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients.

Authors:  Samaresh Sau; Arun K Iyer
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.

Authors:  Zhaoxian Wang; Samaresh Sau; Hashem O Alsaab; Arun K Iyer
Journal:  Nanomedicine       Date:  2018-04-17       Impact factor: 5.307

Review 4.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

5.  Superparamagnetic Hyperthermia Study with Cobalt Ferrite Nanoparticles Covered with γ-Cyclodextrins by Computer Simulation for Application in Alternative Cancer Therapy.

Authors:  Isabela Simona Caizer; Costica Caizer
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

Review 6.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.

Authors:  Xiaopin Duan; Christina Chan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

Review 7.  Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.

Authors:  Rami Alzhrani; Hashem O Alsaab; Alex Petrovici; Ketki Bhise; Kushal Vanamala; Samaresh Sau; Matthew J Krinock; Arun K Iyer
Journal:  Drug Discov Today       Date:  2019-11-20       Impact factor: 7.851

8.  Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer.

Authors:  Yining Zhang; Kevin R Hughes; Ravi M Raghani; Jeffrey Ma; Sophia Orbach; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Biomaterials       Date:  2021-01-08       Impact factor: 12.479

9.  Targeted drug delivery strategies for precision medicines.

Authors:  Mandana T Manzari; Yosi Shamay; Hiroto Kiguchi; Neal Rosen; Maurizio Scaltriti; Daniel A Heller
Journal:  Nat Rev Mater       Date:  2021-02-02       Impact factor: 66.308

10.  Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

Authors:  Masoud Delfi; Rossella Sartorius; Milad Ashrafizadeh; Esmaeel Sharifi; Yapei Zhang; Piergiuseppe De Berardinis; Ali Zarrabi; Rajender S Varma; Franklin R Tay; Bryan Ronain Smith; Pooyan Makvandi
Journal:  Nano Today       Date:  2021-03-11       Impact factor: 18.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.